Our CEO, Line Stigen Raquet, and Michael Hennig from leadXpro sat together and discussed why leadXpro chose the WAVEsystem back in 2017 and how this partnership is creating first‑of‑a‑kind kinetic data. Read all about it on Drug Target Review
Are you attending PEGS Boston Virtual? Make sure you don’t miss our Application Scientist, Dr. Rony Nehmé’s talk on the benefits of early stage kinetic characterization with our WAVEsystem. Expect to see high-quality kinetics in a wide range of crude samples ranging from peptides to membrane proteins and relevant clinical samples.
What? Get ahead in the race, catch the WAVE!
When? September 2nd at 1:25 pm ET & 19:25 CEST & on-demand afterwards.
Where? Online, under biophysical Methods, Analytical Stream.
Creoptix proudly announces its new Board Members, Dr. Chris Radloff and Nicola Bramwell. Dr. Radloff has been elected as new Chairman of the Board of Directors, replacing Eduard M. Brunner and bringing a wealth of experience in the lab instrumentation space. Nicola Bramwell, with over 20 years of experience in commercial roles in the life sciences, comes to further strengthen the Board.
The new Board consists of Dr. Chris Radloff (Chairman), Dr. Robert Schier (Vice Chairman), Jacqueline Ruedin Rüsch, Jon Andri Jörg, Dr. Kaspar Cottier and Nicola Bramwell.
Our CEO, Line Stigen Raquet, was recently interviewed at StartupValley Magazine, where she discussed the secret behind our WAVEsystem, how Creoptix is finding strength in times of COVID19 and the importance of forming and nourishing relationships for long-term success.
Read the full interview (in German) here
Zurich, Switzerland, 13 May 2020 – Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, announced today its collaboration with Adriano Aguzzi, Professor for Neuropathology, University of Zurich, to characterize immunological responses to SARS-CoV-2* such as IgA, IgM and IgG antibodies, which signal whether an individual has been exposed to the Coronavirus.
Prof. Adriano Aguzzi and his team want to understand who has already been infected with SARS-CoV-2 and might be therefore immune. To identify these antibodies in blood samples, the Creoptix WAVEsystem – an extremely sensitive label-free, bioanalytical instrument that enables antibody detection in even pure serum or plasma – will be used.
Line Stigen Raquet, CEO of Creoptix, commented: “The threat posed by COVID-19 demands immediate actions to better understand the mechanisms of this virus in humans. We at Creoptix are tremendously excited and proud to support the efforts of Prof. Aguzzi and his team, who are working on the front lines. We are committed to enabling hospitals and clinical researchers with high performance solutions to characterize binding affinity and kinetics of antibodies on SARS-CoV-2 in conditions closer to real-life. The WAVEsystem’s combination of sensitivity and robustness may prove crucial in shedding light on antibody binding in serum and plasma.”
Creoptix is on a quest to accelerate diagnostics research and help understand immune responses against SARS-CoV-2. “We are fascinated by the idea that our technology could provide new insights in serological testing, guidance in the response to the pandemic and protection of the public’s health,” Line Stigen Raquet explained.
Prof. Adriano Aguzzi, added: “Antibodies are formidable weapons against viruses and that’s the basis of all vaccines. However, antibodies can also facilitate the entry of viruses into cells, thereby causing friendly fire. One determinant of such behaviors is the affinity of antibodies for their targets. In collaboration with Creoptix, we strive to determine the affinity of antisera from COVID-19 patients for their targets. We hope that such investigation may help understand why some patients recover fully from COVID-19 whereas others develop lethal disease.”
* Severe acute respiratory syndrome coronavirus 2, colloquially known as the Coronavirus.
About Creoptix
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and with US offices in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVEsystem provides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics, and other molecules even in biofluids like undiluted serum or plasma. www.creoptix.com
About University of Zurich
The University of Zurich (UZH) is a member of the League of European Research Universities and numbers among Europe’s most prestigious research institutions. UZH’s international standing is reflected in the many renowned academic distinctions conferred upon its members, including twelve Nobel Prizes. As Switzerland’s largest university, UZH has a current enrollment of over 26,000 students and offers the most comprehensive academic program in the country. Nearly 5,000 excellent members of staff teach and perform research at one of the University’s 130 departments, including 675 professors. UZH also looks back on a rich history, having been founded in 1833 as Europe’s first university to be established by a democratic political system.
Contact Creoptix
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Beatrix Benz
This email address is being protected from spambots. You need JavaScript enabled to view it.
+41 79 256 77 73
We’re very much looking forward to help enable scientists to deliver awesome science!
Wädenswil/Zurich, Switzerland, 10 December 2019 – Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020. After seven years in the position, Matyas Vegh has decided to pursue new opportunities outside the company.
“I am grateful to Matyas for his outstanding contributions to the success of Creoptix. Thanks to his achievements, the company is now a well-funded technology leader on a path of accelerated growth. The entire Creoptix team wishes Matyas all the best for his future endeavors,” said Kaspar Cottier, Founder and Chief Technology Officer of Creoptix. “Line joins us at the ideal time as she has an outstanding track record of turning great lab equipment into outstanding commercial successes. We look forward very much to her joining us in January and to benefiting from her experience and leadership qualities as we continue to build Creoptix’ success story.”
Line Stigen Raquet joins Creoptix from Mettler Toledo, where she has most recently served as Vice President of Business Development Life Sciences. Before that she was Head of Strategic Business Unit pH Lab, with full P&L responsibility, significantly accelerating revenue growth over a three-year period across the portfolio of instruments, consumables, software and service. Line was responsible for the entire value chain, from product ideation and development, industrialization, service and end-customer support, marketing and life-cycle management. Prior to Mettler Toledo, Line spent almost a decade at QIAGEN, where she successfully built and led the first APAC regional marketing team in Asia. During her career, she worked in the US, China and the UK before moving to Switzerland.
Line Stigen Raquet commented: “I am incredibly excited to be joining Creoptix at this key stage in its growth. The Creoptix WAVE is a powerful, cutting-edge product portfolio with the potential to bring a paradigm shift in kinetic analysis and molecular characterization and deliver huge benefits to our customers in areas including drug discovery and academia. The team is exceptionally talented and has done a phenomenal job in bringing the portfolio to market. I look forward to driving the next phase of commercial acceleration and unlocking our full potential in this space.”
“Creoptix is expanding its market presence with its next-generation WAVEsystems and seeking to strengthen its commercial operations in Europe and the US. Line is therefore a perfect fit for the business, and we are delighted to welcome her to the team at Creoptix,” added Robert Schier, Vice-Chairman of Creoptix and Investment Director PE/VC Health-Tech at Swisscanto Invest.
About Creoptix
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and with US offices in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVEsystem provides exceptionally high sensitivity and resolution to study real-time biological interactions involving small molecules, peptides, membrane proteins, biologics and other molecules even in biofluids like undiluted serum or plasma. www.creoptix.com
Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Beatrix Benz
This email address is being protected from spambots. You need JavaScript enabled to view it.
+41 79 256 77 73
We are honored by the choice of the Istituto di Cristallografia - CNR Trieste - for our WAVEsystem. As part of the OpenLab2 project (Science Park in Trieste), the WAVEsystem is now available for researchers and companies in the drug discovery field. The system and our GCI technology will be officially presented by our applications scientist, Dr. Fabio Andres, on Tuesday December 3rd at 9:30 at the Sala seminari del CNR “M. Sancrotti” (Piano 1), Palazzina Q2 – Area Science Park – Basovizza, S.S. 14 Km 163,5 Basovizza, Trieste, Italy.
We're looking forward to some high-quality kinetic data soon!
More info here (in italian)
Wädenswil/Zurich, Switzerland, September 30, 2019 – Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, today announced that is has raised CHF 8 million in the first closing as part of a Series C financing round. The round was led by Swisscanto Invest by Zürcher Kantonalbank and joined by Waters Corporation (NYSE: WAT) as well as existing private investors. Robert Schier of Swisscanto Invest has joined the board of directors. With this financing round, the company has raised more than CHF 15 million since 2013. The proceeds enable Creoptix to strengthen its commercial operations in Europe as well as in the US and to expand its market presence.
Creoptix developed and markets Creoptix WAVE systems to study molecular interactions in real-time and is revolutionizing the world of drug discovery. Based on proprietary waveguide interferometry technology, the Creoptix WAVE system offers a level of sensitivity superior to Surface Plasmon Resonance (SPR), with a crude sample robustness normally only achieved with plate-based assays. The technology is facilitating new analytical applications such as membrane protein analysis in drug discovery and real-time kinetic interaction studies in body fluids for biomarker and biotherapeutics development.
Robert Schier, Investment Director PE/VC Health-Tech at Swisscanto Invest, commented: „Creoptix WAVE systems convinces as a mature, robust, versatile and sensitive technology that addresses many existing and novel applications in life sciences. Swisscanto Invest also sees excellent commercial potential, which has been confirmed by existing customers and increasing revenues this year. Creoptix is a great match for our growth fund and we are proud to be part of an exciting journey.“
„We are delighted to have attracted Swisscanto Invest as an institutional investor and are very pleased with the support we have received from our existing investors, including Waters Corporation. This financing round provides us with the funds to support our plans to grow our commercial operations and to expand our market presence to meet the growing need for precise bioanalytical instruments,“ said Matyas Vegh, CEO of Creoptix.
Eduard M. Brunner, Chairman of Creoptix, added: „Creoptix, with its next-generation WAVE systems, has significant potential to make a real impact on the bioanalytical instruments market. We are pleased to welcome Swisscanto Invest as a new investor that will help drive our innovation in the years ahead.“
About Creoptix
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and with US offices in the Boston area. Creoptix focuses on next-generation bioanalytical instruments for drug discovery and development as well as academic research. Based on its proprietary sensor and microfluidics technology, the Creoptix WAVE systems provide exceptionally high sensitivity and resolution in characterizing real-time interactions between small molecules, peptides, proteins and other molecules and even in crude samples like undiluted serum or plasma. www.creoptix.com
About Swisscanto Invest by Zürcher Kantonalbank
Proven specialists develop high-quality investment and pension solutions for private investors, companies and institutions under the Swisscanto Invest by Zürcher Kantonalbank brand. With its Swisscanto Invest by Zürcher Kantonalbank brand, the Zürcher Kantonalbank group is one of Switzerland‘s largest fund providers. It is known for its pioneering role in sustainable investments and its funds regularly achieve national and international recognition. www.swisscanto.ch
About Waters Corporation
Waters Corporation (NYSE: WAT), the world‘s leading specialty measurement company, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With approximately 7,200 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.
www.waters.com
Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
or
Beatrix Benz
This email address is being protected from spambots. You need JavaScript enabled to view it.
+41 79 256 77 73
Our WAVE systems are Genedata compatible, allowing you to analyze data prepared with a Creoptix WAVE or WAVEdelta instrument in your Genedata Screener
Wadenswil, Switzerland, March 1, 2019 - Creoptix AG, a Switzerland-based company focused on next generation bioanalytical instruments, today proudly announced Gareth Jones joining the senior management team as VP Global Sales Operations
“We are very happy to have Gareth joining our company. He brings in vast experience in building up sales teams and establishing innovative new technologies in the analytical instrument business,“ said Matyas Vegh, CEO of Creoptix. “This is exactly what we need now after having generated first momentum with our technology.”
Gareth Jones joins Creoptix coming from TTP Labtech where he held the position of Director of European Sales & Support. Gareth brings over 25 years of commercial experience in the Life science sector, working with several small and large brands like Bio-Rad, Applied Biosystems, Cyntellect and GE Healthcare where he held sales operations or market development positions on European or global level.
“I am truly excited to be joining such a dynamic and innovative company like Creoptix. I believe Creoptix has the technology and capability to transform the way label free analysis is utilised within the drug discovery workflow and provide functionality that has, up until now, not been available with incumbent technology to date.
About Creoptix
Creoptix is a private company headquartered in Wädenswil, near Zurich, Switzerland, and offices near Boston, USA. Creoptix focuses on next generation bioanalytical instruments for drug discovery and development as well as academic research. Based on its proprietary sensor and microfluidics technology, their Creoptix WAVE systems provide exceptionally high sensitivity and resolution in characterizing real-time interactions between small molecules, peptides, proteins and other molecules and in even crude samples like undiluted serum or plasma.
Our biomolecular interactions workshop is taking place on November 9th. Join us for an introduction to GCI, hands-on time with our WAVEdelta and refreshments at the MassBio Collaboration Room, 300 Technology Square in Cambridge, MA.
Click here to register or contact Kevin Jackvony This email address is being protected from spambots. You need JavaScript enabled to view it.
To further strengthen our sales efforts in the US, we proudly welcome Kevin M. Jackvony as National Sales Manager – US & Canada. From his work with several brands like Rainin, GE Healthcare and, most recently, Qiagen. Kevin brings a wealth of capital equipment sales experience to Creoptix. Kevin is based in the Boston area. We hope you will soon have the opportunity to meet him in person.
Creoptix will be participating in the Festival of Biologics 2018, taking place between October 29th-31st in Basel, Switzerland. Free passes are available.
Catch the WAVE of the future in kinetics! Tells us about your wishes in label-free sensing and kinetics.
Link: www.creoptix.com/icatchthenextwave
Wadenswil, Switzerland, September 5, 2018 - Creoptix AG, a Switzerland-based company focused on next generation bioanalytical instruments, today announced it secured new investment in the company from Waters Corporation (NYSE: WAT). Additionally, Geoff Gerhardt, Ph.D.,
Sr. Director, Corporate Development at Waters will join Creoptix board of directors effective immediately.
PRESS RELEASE
Dr. Ulrich Hohmann, from Prof. Michael Hothorn’s group at the University of Geneva, will be talking about LRR-RK signalling during the Peptides and Receptors in Plant Development session that Creoptix is sponsoring on September 6th.
http://www.6th-workshop-plant-peptides-and-receptors.cbgp.upm.es/
Dr. Michael Hennig, CEO of leadXpro, will talk about the company’s experience with the Creoptix WAVE system when measuring ligand binding and kinetics to support drug design on September 27th at 3:55 pm.
The binding kinetics of several approved drugs Danusertib, among others to Aurora A Kinase were recently studied by the lab of Dr. Dorothee Kern at Brandeis University. The group published the results in the open access journal e-Life. (Danusertib, among others)
The Creoptix WAVE system helps reveal new insights in brassinosteroid signalling. The results, obtained by Prof. Michael Hothorn’s group at the University of Geneva, were recently published in Nature Plants.
Prof. Michael Hothorn’s group at the University of Geneva studied the activation of plant membrane receptor kinases with the Creoptix WAVE system. Read all about it in this open access PNAS paper.
Creoptix announces entering UK market with Mologic as first customer and providing new research avenues for Mologic’s Centre for Advanced Rapid Diagnostics (“CARD”) Press Release
We are hiring sales representatives for Europe and the US.
In order to strengthen our sales efforts and our customer support, Creoptix is hiring a Field Application Scientist for the US Territory. Please find the profile here: Field Application Scientist – US Territory
In order to strengthen our sales efforts, Creoptix is seeking a Sales Manager North America. Please find the profile here: Sales Manager North America
Small Molecules can't hide anymore...not even behind large drug targets! Thanks to Novartis for providing the material, our new TechNote shows how Creoptix WAVE pushes the limits regarding sensitivity: Kinetics of a 300Da small molecule with a 110 kDa drug target at Rmax below 1 pg/mm2! Tech Note
Creoptix proudly announces three new Tech Notes demonstrating the benefits of the Creoptix™ WAVE system for molecular interaction analysis:
Fast Off-Rates: Based on very fast injection processes, the Creoptix™ WAVE enables reliable analysis of off-rates of 5 per second! This now allows for off-rate screening and ranking of weak binders such as fragments in a very early discovery process.
Kinetics at High Serum: The innovative disposable microfluidics of the Creoptix™ WAVE provides very high robustness against complex matrices and does not clog at even 100% untreated blood serum. This allows kinetic analysis at much higher serum concentrations than ever before.
Avoiding Mass Transport: Kinetic data quality is significantly impaired by mass transport due to the high immobilization levels required. Thanks to the exceptionally high sensitivity of the Creoptix™ WAVE, reliable kinetics below 1 pg/mm2 are possible and immobilization levels can be markedly reduced. This not only reduces sample consumption but also mass transport limitation.
Creoptix is looking forward to meeting Merck's scientists at the upcoming Merck Technology Symposium taking place on June 2-3, 2015 in Somerset NJ
Creoptix to exhibit at the Drug Discovery Chemistry 2015 in San Diego CA, April 21-23, 2015
Creoptix to exhibit at the Fragments 2015 in Cambridge UK, March 22-24, 2015
Creoptix to exhibit at the Label-Free Technologies Conference in Cambridge MA, March 12-14, 2015
Creoptix proudly announces Dr. Walter Huber as keynote speaker on workshop on March 11 at Swissnex Boston:
Swiss Excellence in Drug Discovery featuring Dr. Walter Huber: "Label-Free Technologies - Overview, Experiences & Perspectives"
Creoptix selected to present at the Late Night with LRIG at the upcoming SLAS2015 in Washington DC. We look forward to seeing you soon in Washinton!
Creoptix to exhibit at the Future Expo during the Eureka Innovation Event and the Swiss Innovation Forum in Basel, Switzerland on November 19 & 20 (Future Expo exhibitor list: DE / ENG)
Creoptix to exhibit at the 10th Annual European Antibody Congress in Geneva, Switzerland on November 10-12, 2014
Creoptix to support the Fragment-based Lead Discovery Conference 2014 in Basel, Switzerland on September 21-24, 2014
Creoptix AG announces carbonic anhydrase data highlighting the exceptional high resolution of the Creoptix™ WAVE system.
Creoptix AG announces the launch of its WAVE system.
We have moved into new facilities, you can now reach us at Einsiedlerstrasse 34, CH-8820 Wädenswil.
Creoptix to support the 15th Annual Drug Discovery Summit in Geneva (press release).